A. Bianco (Napoli, Italy), N. Abu Hussein (Basel, Switzerland)
How COPD patients with Gln27Glu polymorphism utilize exacerbation-related drugs?
K. Dmytriiev (21029, Ukraine), Y. Mostovoy (21029, Ukraine), N. Slepchenko (21029, Ukraine), Y. Smereka (21029, Ukraine), D. Dmytriiev (21029, Ukraine)
|   |
Role of ADRB2 gene haplotypes in the clinical course of COPD
N. Slepchenko (Vinnytsya, Ukraine), Y. Mostovoy (Vinnytsya, Ukraine), K. Dmytriiev (Vinnytsya, Ukraine), Y. Smereka (Vinnytsya, Ukraine), D. Dmytriiev (Vinnytsya, Ukraine)
| |
Serum amyloid A (SAA) as a predictor of chronic obstructive pulmonary disease (COPD) exacerbations.
D. Koval (Dnipro, Ukraine)
| |
Resistin identifies individuals with reduced lung function in a healthy aging cohort.
I. Buendia Roldán (México D.F, Mexico), A. Ruiz (México D.F, Mexico), A. Espinosa-Arellano (México D.F, Mexico), I. Herrera (México D.F, Mexico), L. Chavez-Galan (México D.F, Mexico), M. Selman (México D.F, Mexico)
| |
Activity of platelet von Willebrand factor in stable patients with COPD in terms of cardiovascular risk.
O. Kovalenko (Dnipro, Ukraine), V. Rodionova (Dnipro, Ukraine), O. Boiko (Dnipro, Ukraine)
| |
Connection between markers of local and systemic inflammation in stable COPD
B. Basina (Dnipro, Ukraine), N. Kravchenko (Dnipro, Ukraine), T. Kirieieva (Dnipro, Ukraine), Y. Bershadenko (Dnipro, Ukraine), D. Koval (Dnipro, Ukraine), D. Koval (Dnipropetrovsk, Ukraine)
| |
The prevalence of prolonged QTc and associated risks of starting macrolide treatment
B. Allison (Manchester, United Kingdom), A. Bikov (Manchester, United Kingdom)
| |
Predictive value of caspase-8 in hypertension development in COPD patients
V. Tverezovskyi (Kharkiv, Ukraine), V. Kapustnyk (Kharkiv, Ukraine)
| |
The correlation between blood eosinophilia and clinical characteristics in chronic obstructive pulmonary disease patients
a. chennoufi (tunis, Tunisia), C. Moussa (tunis, Tunisia), H. Rouis (tunis, Tunisia), T. Bejaoui (tunis, Tunisia), I. Khouaja (tunis, Tunisia), M. Bougacha (tunis, Tunisia), S. Neji (tunis, Tunisia), S. Zioueche (tunis, Tunisia), A. Khattab (tunis, Tunisia), L. Bayahi (tunis, Tunisia), I. Zendah (tunis, Tunisia), S. Maalej (tunis, Tunisia), I. Khouaja (Tunis, Tunisia)
| |
Preserved Ratio Impaired Spirometry (PRISM) and increased arterial stiffness (AS)
O. Burghuber (Vienna, Austria), M. Breyer (Vienna, Austria), R. Breyer-Kohansal (Vienna, Austria), P. Puchhammer (Vienna, Austria), A. Ofenheimer (Vienna, Austria), C. Kaufmann (Vienna, Austria), T. Weber (Wels, Austria), S. Hartl (Vienna, Austria)
| |
Role of the lower limit of normal in COPD diagnosis.
A. Martín Hernández (Madrid, Spain), M. Solís García (Madrid, Spain), L. García Castellanos (Madrid, Spain), M. Hevia Menéndez (Madrid, Spain), E. Martínez Besteiro (Madrid, Spain), J. Eiros Bachiller (Madrid, Spain), C. Marcos (Madrid, Spain), R. Gómez-Punter (Madrid, Spain), E. Ávalos Pérez-Urria (Madrid, Spain), G. Iturricastillo Gutiérrez (Madrid, Spain), J. Ancochea Bermúdez (Madrid, Spain)
| |
Impulse oscillometry as a rule-out method for emphysema
A. Klitgaard (Vejle, Denmark), A. Løkke (Vejle, Denmark), O. Hilberg (Vejle, Denmark)
| |
Association between thoracic muscle mass assessed by high-resolution computed tomography and static lung volume in patients with COPD - a pilot study
M. Brath (Aalborg, Denmark), E. Mark (Aalborg, Denmark), J. Frøkjær (Aalborg, Denmark), P. Veiss-Pedersen (Aalborg, Denmark), L. Østergaard (Aalborg, Denmark), H. Rasmussen (Aalborg, Denmark), U. Weinreich (Aalborg, Denmark)
| |
What are the best spirometric predictors of COPD progression?
B. Basina (Dnipro, Ukraine), T. Pertseva (Dnipro, Ukraine), N. Kravchenko (Dnipro, Ukraine), D. Koval (Dnipro, Ukraine), D. Koval (Dnipropetrovsk, Ukraine)
| |
Effect of an early multidisciplinary respiratory (MDT) in-reach review of Airways Disease exacerbations (ADE) in an acute general hospital on discharges and length of stay (LOS)
A. Al Helou (Birmingham, United Kingdom), G. Chellappah (Birmingham, United Kingdom), P. Ellis (Birmingham, United Kingdom), K. Jones (Birmingham, United Kingdom), A. Mansur (Birmingham, United Kingdom), R. Mukherjee (Birmingham, United Kingdom)
| |
The language COPD patients use to describe exacerbations: a qualitative study
M. Crooks (East Riding of Yorkshire, United Kingdom), R. Russell (Oxford, United Kingdom), H. Cummings (East Riding of Yorkshire, United Kingdom), K. Roy (London, United Kingdom), O. Usmani (London, United Kingdom), S. Macfadyan (London, United Kingdom), J. Cohen (Hull, United Kingdom), T. Morris (Luton, United Kingdom), H. Mullerova (Luton, United Kingdom), Y. Xu (Luton, United Kingdom), A. Hutchinson (East Riding of Yorkshire, United Kingdom)
| |
Predicting 3-month respiratory readmission in a Scottish COPD cohort
S. Burns (Edinburgh, United Kingdom), A. Taylor (Glasgow (Glasgow), United Kingdom), G. Cox (Edinburgh, United Kingdom), P. Mcginness (Edinburgh, United Kingdom), D. Lowe (Glasgow (Glasgow), United Kingdom), C. Carlin (Glasgow (Glasgow), United Kingdom)
| |
Restrictive and obstructive lung patterns and postoperative pulmonary complications after cardiac surgeries: A prospective cohort study
H. Sadeghi (Tehran, Islamic Republic of Iran), M. Mirdamadi (Tehran, Islamic Republic of Iran), M. Sheikh Fathollahi (Tehran, Islamic Republic of Iran), S. Sarina (Tehran, Islamic Republic of Iran)
| |
Proadrenomedullin and copeptin are more sensitive and specific biomarkers for the prediction of mortality in stable COPD than fibrinogen: An analysis of the COSYCONET study
S. Fähndrich (Freiburg, Germany), S. Teuteberg (Freiburg, Germany), C. Herr (Homburg/Saar, Germany), H. Watz (Großhansdorf, Germany), B. Waschki (Großhansdorf, Germany), F. Trudzinski (Heidelberg, Germany), A. Omlor (Homburg/Saar, Germany), P. Alter (Marburg, Germany), F. Seiler (Homburg/Saar, Germany), F. Biertz (Hannover, Germany), T. Welte (Hannover, Germany), H. Kauczor (Heidelberg, Germany), R. Jörres (München, Germany), C. Vogelmeier (Marburg, Germany), R. Bals (Homburg/Saar, Germany), D. Stolz (Freiburg, Germany)
| |
Comparison of predictive properties between tools of patient-reported outcomes: exacerbation and admission due to exacerbation in subjects with chronic obstructive pulmonary disease.
K. Nishimura (Obu, Japan), M. Mori (Obu, Japan), R. Sanda (Obu, Japan), M. Kusunose (Obu, Japan)
| |